Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Frontiers in Immunology
|
September 6, 2023
A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome
John Marsiglio, Jordan P McPherson, Magdalena Kovacsovics-Bankowski, et al.
Journal of the National Cancer Institute
|
August 21, 2025
Tattooing and risk of melanoma: a population-based case-control study in Utah
Rachel D McCarty, Britton Trabert, Lindsay J Collin, et al.
Research Square
|
July 3, 2023
Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis
Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
Melanoma Research
|
August 12, 2017
Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis
Laura J Gardner, Morgan Ward, Robert H I Andtbacka, et al.
Current Oncology (Toronto, Ont.)
|
March 26, 2025
Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma
Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
Journal for Immunotherapy of Cancer
|
January 17, 2024
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4<sup>+</sup> naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Magdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, et al.
Cancer Medicine
|
May 13, 2021
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
Robert C Chick, Mark B Faries, Diane F Hale, et al.
Melanoma Research
|
July 1, 2021
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma
Alexandra M Adams, Robert C Chick, Timothy J Vreeland, et al.
Journal for Immunotherapy of Cancer
|
August 3, 2023
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
Elizabeth Lee Carpenter, Spencer Van Decar, Alexandra M Adams, et al.
Cancer Treatment and Research Communications
|
September 21, 2024
Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial
Spencer G Van Decar, Elizabeth L Carpenter, Alexandra M Adams, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Frontiers in Immunology
|
September 6, 2023
A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome
John Marsiglio, Jordan P McPherson, Magdalena Kovacsovics-Bankowski, et al.
Journal of the National Cancer Institute
|
August 21, 2025
Tattooing and risk of melanoma: a population-based case-control study in Utah
Rachel D McCarty, Britton Trabert, Lindsay J Collin, et al.
Research Square
|
July 3, 2023
Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis
Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
Melanoma Research
|
August 12, 2017
Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis
Laura J Gardner, Morgan Ward, Robert H I Andtbacka, et al.
Current Oncology (Toronto, Ont.)
|
March 26, 2025
Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma
Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
Journal for Immunotherapy of Cancer
|
January 17, 2024
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4<sup>+</sup> naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Magdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, et al.
Cancer Medicine
|
May 13, 2021
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
Robert C Chick, Mark B Faries, Diane F Hale, et al.
Melanoma Research
|
July 1, 2021
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma
Alexandra M Adams, Robert C Chick, Timothy J Vreeland, et al.
Journal for Immunotherapy of Cancer
|
August 3, 2023
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
Elizabeth Lee Carpenter, Spencer Van Decar, Alexandra M Adams, et al.
Cancer Treatment and Research Communications
|
September 21, 2024
Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial
Spencer G Van Decar, Elizabeth L Carpenter, Alexandra M Adams, et al.
Page
of 3